Vigeo Therapeutics is building a therapeutic pipeline aimed at reinvigorating the immune system for the treatment of immunological and inflammatory disorders, such as neurodegenerative disease and cancer. They are harnessing the power of cytokine modulation, specifically targeting the signaling pathways involved in immune dysregulation. Vigeo Therapeutics employs advanced biologics and small molecule therapies designed to selectively modulate immune responses, aiming to achieve therapeutic efficacy while minimizing adverse effects. Through rigorous scientific research and innovative drug development strategies, Vigeo Therapeutics seeks to address unmet medical needs and improve the lives of patients affected by these complex and challenging conditions.

Vigeo Therapeutics

Founded: 2011
Location: Cambridge, MA
Employee range: 1 - 10
Clinical stage: Clin1/Clin2
Therapy area: Glioblastoma
Drug types: ONC
Lead product: VT1021

Drug notes:

About:

Jobs: